Document Detail


Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure.
MedLine Citation:
PMID:  20176990     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Previous studies suggest that management of ambulatory hemodynamics may improve outcomes in chronic heart failure. We conducted a prospective, observational, first-in-human study of a physician-directed patient self-management system targeting left atrial pressure. METHODS AND RESULTS: Forty patients with reduced or preserved left ventricular ejection fraction and a history of New York Heart Association class III or IV heart failure and acute decompensation were implanted with an investigational left atrial pressure monitor, and readings were acquired twice daily. For the first 3 months, patients and clinicians were blinded as to these readings, and treatment continued per usual clinical assessment. Thereafter, left atrial pressure and individualized therapy instructions guided by these pressures were disclosed to the patient. Event-free survival was determined over a median follow-up of 25 months (range 3 to 38 months). Survival without decompensation was 61% at 3 years, and events tended to be less frequent after the first 3 months (hazard ratio 0.16 [95% confidence interval 0.04 to 0.68], P=0.012). Mean daily left atrial pressure fell from 17.6 mm Hg (95% confidence interval 15.8 to 19.4 mm Hg) in the first 3 months to 14.8 mm Hg (95% confidence interval 13.0 to 16.6 mm Hg; P=0.003) during pressure-guided therapy. The frequency of elevated readings (>25 mm Hg) was reduced by 67% (P<0.001). There were improvements in New York Heart Association class (-0.7+/-0.8, P<0.001) and left ventricular ejection fraction (7+/-10%, P<0.001). Doses of angiotensin-converting enzyme/angiotensin-receptor blockers and beta-blockers were uptitrated by 37% (P<0.001) and 40% (P<0.001), respectively, whereas doses of loop diuretics fell by 27% (P=0.15). CONCLUSIONS: Physician-directed patient self-management of left atrial pressure has the potential to improve hemodynamics, symptoms, and outcomes in advanced heart failure. Clinical Trial Registration Information- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00547729.
Authors:
Jay Ritzema; Richard Troughton; Iain Melton; Ian Crozier; Robert Doughty; Henry Krum; Anthony Walton; Philip Adamson; Saibal Kar; Prediman K Shah; Mark Richards; Neal L Eigler; James S Whiting; Garrie J Haas; J Thomas Heywood; Christopher M Frampton; William T Abraham;
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2010-02-22
Journal Detail:
Title:  Circulation     Volume:  121     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-09     Completed Date:  2010-03-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1086-95     Citation Subset:  AIM; IM    
Affiliation:
University of Otago, Christchurch, New Zealand.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00547729
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / administration & dosage,  therapeutic use
Aged
Aged, 80 and over
Angiotensin II Type 1 Receptor Blockers / administration & dosage,  therapeutic use
Angiotensin-Converting Enzyme Inhibitors / administration & dosage,  therapeutic use
Blood Pressure Monitoring, Ambulatory* / instrumentation,  methods
Combined Modality Therapy
Double-Blind Method
Electrodes, Implanted
Equipment Design
Female
Heart Atria
Heart Failure / drug therapy,  mortality,  physiopathology,  therapy*
Hemodynamics
Humans
Kaplan-Meiers Estimate
Male
Middle Aged
Pacemaker, Artificial
Prospective Studies
Self Care*
Sodium Potassium Chloride Symporter Inhibitors / administration & dosage,  therapeutic use
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Sodium Potassium Chloride Symporter Inhibitors
Investigator
Investigator/Affiliation:
J Aw / ; D Kaye / ; H Krum / ; T Waltoon / ; R Doughty / ; J Stewart / ; N Eigler / ; S Kar / ; R Makkar / ; P K Shah / ; R Siegel / ; J Whiting / ; I Crozier / ; J Lainchbury / ; I Melton / ; M Richards / ; J Ritzema-Carter / ; G Roper / ; R Troughton / ; W T Abraham / ; P Binkley / ; C Bush / ; G Cooke / ; D Feldman / ; D Hart / ; G Haas / ; A Hasan / ; M Houmsse / ; C Leir / ; C Love / ; R Magorien / ; R Mehta / ; B White / ; P Adamson / ; M Harvey / ; T Ahern / ; T Heywood / ; A Johnson / ; M Price / ; R Schatz / ; C Stinis / ; P Teirstein / ; B Greenberg / ; M Mehra / ; J McAnulty / ; M Klapholz / ; M Semigran / ; D Benditt /

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mechanical Dyssynchrony After Myocardial Infarction in Patients With Left Ventricular Dysfunction, H...
Next Document:  Notch signaling regulates endothelial progenitor cell activity during recovery from arterial injury ...